Submit Modified Informed Consent Form with details: CDSCO Panel Tells Sanofi om Multiple Sclerosis Drug Tolebrutinib

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-21 12:30 GMT   |   Update On 2024-03-22 16:33 GMT
Advertisement

New Delhi: Reviewing the Phase III clinical study protocol of Tolebrutinib presented by the drug major Sanofi, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm submit the modified Informed Consent Form mentioning the details about 11 times visit to the site.

Furthermore, the expert panel suggested the firm to submit the volume of samples to be collected and compensation to be paid in case of a visit to the site or home visit, clearance for shipping of samples outside the country, if any, and written assurance for a home visit if the patient is unable to visit the site.

Advertisement

This came after the drug major Sanofi presented phase III clinical study protocol no. LTS17043.

Tolebrutinib is a new drug being investigated for the treatment of relapsing, secondary, and primary progressive multiple sclerosis.

Tolebrutinib, a CNS-penetrant BTK inhibitor, has a dual mechanism of action, acting on both adaptive and innate immunity. Bruton's tyrosine kinase mediates adaptive immunity by coupling the antigenic stimulation of the B-cell receptor to nuclear signaling that leads to acute inflammatory responses.

At the recent SEC meeting for Neurology and Psychiatry held on 20th December 2023, the expert panel reviewed the Phase III clinical study of the multiple sclerosis drug Tolebrutinib.

After detailed deliberation, the committee opined that the firm should submit the following for review by the committee:

1. Modified Informed Consent Form mentioning the details about 11 times visit the site, volume of sample to be collected, and compensation to be paid in case of a visit to the site or home visit.

2 Clearance for shipping of samples outside the country, if any.

3. Written assurance for home visit if the patient is unable to visit the site.

Also Read: Dr Mansukh Mandaviya inaugurates CDSCO Sub Zonal Office, Central Drug Testing Laboratory in Indore

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News